Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises when Lendify, a digital lender and one of Sweden’s largest challengers to the banking sector, reaches a billion valuation in conjunction with new capital raising
Mandate

Vinge advises when Lendify, a digital lender and one of Sweden’s largest challengers to the banking sector, reaches a billion valuation in conjunction with new capital raising

September 10, 2019 M&A

Vinge has advised Lendify AB (publ) (”Lendify”) in connection with the procurement of new capital in an investment round in a total amount of approximately SEK 197 million.

The issue occurs to a valuation of Lendify of approximately SEK 1 billion (prior to the investment). The capital is intended to be used for capital adequacy and future liquidity.

Vinge’s team primarily consisted of partner Jonas Johansson together with, among others, associates Filip Öhrner, Anna Thoms and Hanna Risberg.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026